[Quality of Life Is Associated with Combined Lenalidomide and Dexamethasone Treatment in Japanese Patients with Relapsed or Refractory Multiple Myeloma].
This study investigated the relationship between quality of life (QOL) and efficacy or occurrence of adverse events in patients who were administered lenalidomide and dexamethasone (Len+Dex) therapy for relapsed or refractory multiple myeloma (MM) in the hematology department at Obihiro Kosei Hospital from September 2010 to September 2012. QOL was evaluated using a quality of life questionnaire for cancer patients treated with anticancer drugs (QOL-ACD). The average QOL score of 7 patients receiving 4 cycles of Len+Dex treatment decreased 5 points from baseline Len+Dex treatment. The change in QOL score was significantly correlated with changes in serum M-protein (correlation coefficient: R=0.777). However, there was no significant correlation between adverse events and the change in QOL score. Our results indicate that QOL may be improved by the effects of Len+Dex treatment.